Table of Contents
VIOXX™ Gastrointestinal Outcome Research (VIGOR) Arthritis Advisory Committee Meeting February 8, 2001
VIGOR Study Design
VIGOR Study Design Dose
VIGOR Study Design Relevance of the 50 mg Dose
VIOXX 50 mg usage data*
VIGOR Study Design Population
VIGOR Study Design Endpoints - Safety
VIGOR Study Design Endpoints - Efficacy
VIGOR Study Issues
FDA speakers
|
Author: CDER User
|